key: cord-0078833-q31720gy
authors: Voisin, Mathew R; Oliver, Kathy; Farrimond, Stuart; Chee, Tess; O’Halloran, Philip; Glas, Martin; Arzbaecher, Jean; Kruchko, Carol; Maher, Mary Ellen; Tse, Chris; Cashman, Rosemary; Daniels, Maureen; Mungoshi, Christine; Lamb, Sharon; Granero, Anita; Lovely, Mary; Baker, Jenifer; Payne, Sally; Zadeh, Gelareh
title: Brain tumour patients and COVID-19 vaccines: results of an international survey
date: 2022-05-03
journal: Neurooncol Adv
DOI: 10.1093/noajnl/vdac063
sha: cfb762709868a9632e03c12ad10800a4e924bd93
doc_id: 78833
cord_uid: q31720gy

BACKGROUND: As the COVID-19 pandemic continues to unfold, the advent of multiple approved vaccines has led to a milestone in the fight against the virus. While vaccination rates and side effects are well established in the general population, these are largely unknown in patients with brain tumours. The purpose of this study was to determine if brain tumour patients and their caregivers have received a COVID-19 vaccine, and explore their thoughts and opinions on these vaccines. METHODS: An anonymous 31-question online survey available in eight languages was conducted from June 30, 2021 to August 31, 2021. The survey was open to adult brain tumour patients over the age of 18 and included both categorical and open-ended questions. Descriptive statistics and modified thematic analyses were performed for all questions as appropriate. RESULTS: A total of 965 unique surveys were completed from 42 countries. The vast majority of both brain tumour patients and their caregivers have been vaccinated against COVID-19 (84.5% and 89.9%, respectively). No patient reported serious adverse events from any vaccine. Less than 10% of patients decided against receiving a vaccination against COVID-19, with the most common reason being concerns over the safety of the vaccine. Patients wanted more specific information on how COVID-19 vaccines might impact their future brain tumour treatment. CONCLUSIONS: In conclusion, the majority of brain tumour patients and their caregivers have received COVID-19 vaccines with no major side effects. Patients want more information on how COVID-19 vaccines might directly impact their brain tumour and future management.

This is the first international survey completed with the purpose of determining if adult brain tumour patients and their caregivers have been vaccinated against COVID-19 and their thoughts and opinions on the vaccines. Overall, we had close to 1000 unique responses from over 40 countries when the survey was conducted in July and August of 2021. Results demonstrated that the vast majority of brain tumour patients and their caregivers have been vaccinated against COVID-19 with no major side effects reported. Less than 10% of patients decided against vaccination, with the main concern over the safety of COVID-19 vaccines. A common theme emerged of patients wanting more specific information on how these vaccines might interact with their brain tumour directly, or indirectly impact their future brain tumour treatment.

A c c e p t e d M a n u s c r i p t 6 Introduction:

As the global COVID-19 pandemic continues, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there have been over 500 million confirmed cases of COVID-19, including over six million deaths as of April19, 2022. 1 With the realization that vaccines could play an essential role in increasing immunity and preventing disease, a global vaccine race commenced in early 2020 with a focus on the development, manufacturing, and distribution of vaccines. 2 The ChAdOx1 nCoV-19 vaccine (AZD1222), also known as the Oxford University / AstraZeneca vaccine (brand name Vaxzevria), was the first COVID-19 vaccine to be developed. 3 It was developed at the University of Oxford Jenner Institute in early 2020 and the university and AstraZeneca announced a global development agreement on April 30, 2020. 3 Similarly, the BNT162b2 vaccine, commonly known as the Pfizer-BioNTech vaccine or brand name Comirnaty, began development early in 2020 as well. 4 The third major vaccine, mRNA-1273 or the Moderna vaccine (brand name Spikevax), was developed in collaboration with the National Institute of Health (NIH) in the United States in February of 2020 and the first patient in their Phase 1 study was dosed on March 16, 2020. 5 On December 2, 2020, the United Kingdom became the first country to approve a COVID-19 vaccine, the Pfizer-BioNTech vaccine, for emergency use, after being tested in a large clinical trial. 6 Similarly, the United States Food and Drug Administration (FDA) approved both Pfizer-BioNTech and the Moderna COVID-19 vaccines in December 2020 for emergency use authorization. 7 The Pfizer-BioNTech vaccine went on to be the first vaccine to receive FDA approval on August 23, 2021 for individuals ages 16 and older. 8 As of April 19, 2022, there are currently 195 vaccines in development, with 687 active vaccine trials in 75 different countries, including a majority of phase II and III trials. 9 As of April 19, 2022, the World Health Organization (WHO) has approved 38vaccines for use against COVID-19, with over 11 billion vaccine doses having already been administered worldwide. 1, 9 A c c e p t e d M a n u s c r i p t 7 While extensive vaccination research has been done and is ongoing, the vaccination status, impact, and programs affecting brain tumour patients worldwide was unknown. To better understand how brain tumour patients have been prioritized and responded to the emerging role of COVID-19 vaccination utility, the International Brain Tumour Alliance (IBTA) developed an anonymous international survey that was available for completion during July and August of 2021. This is the third international survey undertaken by the IBTA during the COVID-19 pandemic. The first two surveys, completed in 2020, examined the effects of the early COVID-19 pandemic on brain tumour patients, their caregivers, and brain tumour notfor-profits and charities. 10, 11 The vaccines survey focused on adult brain tumour patients and their caregivers. The purpose of the study was to determine if this population has received any COVID-19 vaccine, and explore the experiences, side effects, thoughts, and opinions of vaccination in this unique population.

An anonymous online survey was developed by the International Brain Tumour Alliance (IBTA) as part of the continued work of the Society for Neuro-Oncology (SNO) COVID-19

Task Force. The 31-question survey was available in eight languages (English, French, German, Italian, Japanese, Polish, Spanish, and Urdu) and included a mixture of both categorical and qualitative, open-ended questions. Informed consent was obtained from each participant prior to survey commencement. Translation support was provided by individual members of SNO, the international brain tumour patient advocacy community, and outside translation agencies. Table 1 lists all 31 questions included in the survey. The survey was globally disseminated to over 120 brain tumour charities and not-for-profits and brain tumour healthcare professionals to distribute to their patients. Responses were collected over two A c c e p t e d M a n u s c r i p t 8 months from June 30, 2021 to August 31, 2021, inclusive. The survey was open to adult brain tumour patients over the age of 18 because at the time of the survey the majority of countries had not started vaccinating individuals under the age of 18. This was prior to countries providing COVID-19 booster / third dose vaccines. The data from this survey includes only the first two vaccination doses.

Responses were grouped into the following five categories: patient demographics, COVID-19 testing and vaccination status, vaccination programs, vaccination hesitancy and side effects, and caregiver vaccination status and views. Descriptive statistics were applied for all categorical questions. Open-ended, qualitative questions were reviewed using modified thematic analysis where overarching themes are extracted from the written answers. 12 This approach uses both open coding (fragments are grouped according to shared ideas) and axial coding (dominant ideas are organized into overarching themes). 12 All text responses for all questions were independently reviewed by two researchers to ensure accurate capture of overarching themes and ideas.

Overall, 965 unique surveys from adult brain tumour patients were completed from a total of 

Of those brain tumour patients who received their first one or two COVID-19 vaccinations, 55.2% (N = 428) were prioritized by their country's government. From this question concerning vaccine prioritization, 101 patients (13%) reported they had not yet received any COVID-19 vaccine at the time of the survey. The most common reason reported in the survey for prioritization to receive the COVID-19 vaccine was a brain tumour diagnosis (30.8%, N = 227), followed by age (16.4%, N = 121), and other medical conditions (9.5%, N = 70). Freetext survey responses indicated that a more specific cause of being prioritized was that the patient was actively undergoing chemotherapy treatment. In total, 80.9% (N = 564) of A c c e p t e d M a n u s c r i p t 11 patients who responded to the survey felt they had received sufficient information about the COVID-19 vaccines. Free-text responses from patients who felt they had received inadequate information included the common concern regarding the need for more information about potential COVID-19 vaccine side effects specifically on brain tumour patients and brain tumour treatments. Another common theme was the general need for more information on long-term vaccine side effects, and also specifically for brain tumour patients. 

A total of 7.5% (N = 51) patients responded that they have decided not to receive any COVID-19 vaccine. A total of 84 patients addressed various concerns about COVID-19 vaccines as reasons to not receive the vaccine. The most commonly cited vaccine concern was regarding the vaccine's safety (52.4%, N = 44), followed by uncertainty about the vaccine's efficacy (21.4%, N = 18). Some patients responding to the survey stated that they felt the vaccine was unnecessary (15.5%, N = 13). Free-text responses were divided into two themes; lack of trust in the vaccine and hesitancy due to brain tumour diagnosis and/or treatment.

One patient responded: -I'm worried about potential side effects as I have recently undergone treatment for my brain tumour. I support vaccination and intend to get vaccinated once more people in my country have been vaccinated and there is more research/data about the vaccines‖ Table 3 lists the reported side effects from brain tumour patients receiving any COVID-19 vaccine alongside information from the Centers for Disease Control and Prevention (CDC) collected from the general population receiving the Pfizer / BioNTech vaccine (the most common vaccine administered to brain tumor patients according to our survey). 13 The most common side effects from receiving either the first or the second dose were pain in the arm Free-text responses from those who responded that their routine has changed (3.6%, N = 24) reported that their caregiver was now able to accompany them to medical appointments or that the brain tumour patient and their caregiver went into stores or outside of the house more often than prior to vaccination. A total of 31.6% (N = 87) had their caregiver help them complete the survey.

The final survey question asked if there were any other comments patients would like to pass on to those responsible for vaccination programs. The overwhelming majority of responses focused on the perceived need for brain tumour patients and their caregivers to be prioritized for vaccination. A common theme was the desire for more transparent and clear information on vaccine safety to impact on brain tumour patients and their treatments. Patients reported struggling to find clear and reliable information about COVID-19 vaccine that is specifically relevant and applicable to them. were not yet routinely being administered or available. In total, we received 965 unique survey responses from 42 countries. While this survey was limited to adult patients only, the overall makeup of respondents was very similar to the first global IBTA survey regarding the most common brain tumour diagnoses of GBM, meningioma, and lower-grade gliomas and medical co-morbidities. 11 Overall, while the majority of respondents (69%) had been tested for COVID-19 at the time of the survey, only a small percentage (6%) of respondents had tested positive for COVID-19. In comparison, according to the CDC, the cumulative percent positivity in the United States for nucleic acid amplification tests (NAATs) at the time of the survey was 8.1% and was 9.5% as of February 27, 2022. 14 Our survey did not clarify what percentage of COVID-19 testing performed was symptomatic vs asymptomatic or mandatory due to a hospital or clinic visit, but there does not seem to be a large discrepancy between the number of brain tumour patients that have tested positive for COVID-19 compared to the general population.

The vast majority of both brain tumour patients and their caregivers had received one or two doses of any COVID-19 vaccine at the time of the survey (84.5% and 89.9%, respectively).

The rate of vaccination in brain tumor patients and their caregivers is higher than the general population rates of vaccination at the time of the survey for both the United States (58.7%) and the United Kingdom (80.8%). 14, 15 The majority of brain tumour patients and their A c c e p t e d M a n u s c r i p t 15 caregivers received the Pfizer / BioNTech vaccine (53.3%) which is in keeping with CDC and National Health Service (NHS) data on United States and the United Kingdom vaccination type. 14,16 There were no major side effects reported by respondents to any of the vaccine types. Minor side effects reported by brain tumor patients including both local and systemic appeared to be notably less than those reported by the general population (Table 3) . Most brain tumour patients who had a two-dose vaccine received their second dose within six weeks or less (65.4%) however approximately a quarter of brain tumour patients (26.4%) were on active treatment for their brain tumour when they received their COVID-19 vaccination, with most patients receiving chemotherapy when they were vaccinated. Recent research has highlighted that cancer patients on active treatment including chemotherapy are at a higher risk of a fatal outcome due to COVID-19 infection. 17 While guidelines surrounding chemotherapy reinforce the safety of non-live vaccines during treatment, patients may be less likely to mount an optimal immune response necessary for full immunity. 18 The majority of brain tumour patients (55.2%) were also prioritized by their government to receive a COVID-19 vaccine, with approximately one third of respondents (30.8%) prioritized due to their brain tumour diagnosis. While our survey did not clarify whether all individuals with cancer in their countries were prioritized compared to specifically brain tumour patients only, there is an overwhelming agreement that individuals with cancer should be prioritized for COVID-19 vaccination. 17 Despite this, almost one third of respondents (31.7%) had concerns about the COVID-19 vaccination program in their country, including frustration on the changing interval timings between vaccine doses and vaccine prioritization.

Some respondents mentioned that their brain tumour diagnosis itself was not prioritized, and indeed, sub-prioritization schedules for cancer patients have been described, including cancer stage, type, and other individual risk factors such as age. 19 A c c e p t e d M a n u s c r i p t 16 Overall, 7.5% of respondents had decided not to receive any COVID-19 vaccination at the time of the survey. As multiple questions asked if respondents had received the vaccine, there was some discrepancy in the number of patients that reported they had not received the vaccine due to variability in response rates for each question. Approximately 12-13% of respondents had not yet received the vaccine, depending on the question (85-101 respondents). This discrepancy may have been due to respondents being able to choose which questions of the survey to answer. Of those 85 to 101 respondents who had not yet received any vaccination, at least half of them had actively chosen not to receive the vaccine (51 respondents), and 84 respondents mentioned concerns about COVID-19 mRNA vaccines specifically as a reason not to receive the vaccine. The largest concern stated by respondents choosing not to receive the vaccine was the safety of the vaccine. Another interesting and common response for vaccine hesitancy was the unknown effects of the vaccine on patients with brain tumours. This was a common theme throughout the free-text responses.

In comparing vaccine hesitancy rates from prior studies, a systematic review of global COVID-19 vaccine hesitancy published in 2021 reported that the majority of countries included in the study had vaccine hesitancy rates of 30% or less, with the United States having one of the highest vaccine hesitancy rates of 43.1%. 20 Previously published studies on blood cancer patients and individuals with cancer or other serious comorbid conditions found that vaccine hesitancy rates amongst these populations was 17% and 18.6%, respectively. 21, 22 Overall, vaccine hesitancy rates amongst brain tumor patients were lower than both the general population and other high-risk groups, and respondents wanted more specific information on how COVID-19 vaccines might directly impact their brain tumour prognosis and treatment. Brain tumor patients also experienced no major side effects and fewer minor side effects than the general population. Respondents also largely focused on the need for brain tumour patients and their caregivers to be prioritized for vaccination and for more A c c e p t e d M a n u s c r i p t 17 transparent information concerning vaccine safety and impact from healthcare professionals and the government.

Similar to the first IBTA survey carried out in early 2020 and directed to brain tumour patients (adult and pediatric) and their caregivers, this survey consisted of self-selected volunteers and therefore, there may be response bias in these results. In this survey, it was not required for survey respondents to complete every question before submitting the survey, and because of this the response rate for each question is variable. Overall, the majority of questions had a response rate of 70-80%, while other more particular questions such as those specific to patients with caregivers or those that had vaccine hesitancy returned a 30% response rate. In addition, there may have been selection bias because this survey was widely distributed through brain tumour charities and not-for-profits, and the patients and caregivers who completed the survey may not be representative of the entire population. The majority of responses came from countries including the United States, Western Europe, and Japan, and the results may not be reflective of all countries or regions. Furthermore, there is a chance that some people did not do the survey because they had yet to be vaccinated, which is also a form of selection bias. Those patients without a connection to a brain tumour charity or notfor-profit may not have been able to learn about and thereby choose to complete the survey.

There may also have been challenges with informing patients from underserved and under- 

In conclusion, the majority of brain tumour patients and their caregivers worldwide have been vaccinated against COVID-19 with no major reported vaccine side effects. Despite this, there was still a large advocacy effort to continue prioritization of COVID-19 vaccination and timely delivery of vaccinations in brain tumour patients and their caregivers. The minority of patients who chose not to receive the vaccine were concerned with the vaccine's safety and any potential direct and indirect effects the vaccine may have on brain tumours and brain tumour treatments. As we move into this current age of booster doses and novel variants, it is important to continue to research the effects of vaccines on brain tumours and patient care and advocate for these vulnerable populations most at risk of COVID-19. A c c e p t e d M a n u s c r i p t 27 

World Health Organization (WHO). (2022) Coronavirus (COVID-19) Dashboard

The race to make a COVID-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Moderna's Work on our COVID-19 Vaccine

Accessed

The UK has approved a COVID vaccinehere's what scientists now want to know

First month of COVID-19 vaccine safety monitoring-United States

Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY) Overview and Safety

The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century

Basics of qualitative research

2022) Vaccines & Immunizations. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events

2022) COVID Data Tracker

Coronavirus (COVID-19) in the UK: Vaccinations in United Kingdom

COVID-19 Vaccinations

Accessed